Close Menu

At In the Pipeline, Derek Lowe asks in which fields people would consider starting a small drug company. He writes that oncology would have been a good choice a decade ago and that going into cardiovascular disease and metabolic disorders doesn’t make much sense, unless you've been sitting on a golden egg. Alzheimer's disease, he says, is an under-served market, adding that "it's unserved for a lot of damned good reasons. The same goes for a number of other CNS indications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.